Nevada Organic Phosphate Inc. reported that drill hole MM26-11 intersected 28.7 meters of the target Meade Peak Member, confirming phosphate mineralization over a strike length of more than 3.3 kilometers. The drill core showed typical oolitic zones of the Upper Phosphate Zone, with assays pending to confirm thickness and phosphate content. The company noted drilling challenges due to complex geology but continues to advance exploration in northeast Nevada, aiming to define a large-scale organic sedimentary phosphate deposit. This progress supports their geological model and the potential for a significant phosphate resource in North America.
Nevada Organic Phosphate's recent drilling update provides context for readers interested in basic materials. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Oct 19, 2026 14:31 WIB: out of 83 priced US stocks, 62 rose and 17 fell. Notable movers include Novagold Resources Inc. (NG) at USD 6.60 with a 5.94% increase, i-80 Gold Corp. (IAUX) at USD 1.52 up 5.56%, and Century Aluminum Company (CENX) at USD 35.03 rising 5.45%.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
